Skip to content
OpenCapital
Get started

Catalyst Pharmaceutical CPRX Enterprise value

Enterprise value at other companies

PTC Therapeutics logo
PTC TherapeuticsPTCT
$5.2B+77.3%
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
$3.35B+63.5%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$3.56B+36.6%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$2.41B+228%
Scholar Rock logo
Scholar RockSRRK
$5.42B+82.6%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$6.34B+33.4%

Other financials

Income statement

See full
Revenue$149.4M+5.6%
Gross profit$134.9M+9.2%
Operating income$73.2M+15.6%
Net income$63.7M+12.3%
EPS (diluted)$0.50+11.1%

Balance sheet

See full
Cash & equivalents$755.9M+30.2%
Total debt$2.7M-13.3%
Total equity$1.0B+27.5%
Total assets$1.1B+26.3%

Cash flow

See full
Operating cash flow$59.6M-0.8%
CapEx$27.0K—
Free cash flow$59.6M-0.8%

Valuation

See full
Market cap$3.84B+2.7%
P/E17.4×-1.6×
P/S6.4×-0.6×

Profitability

See full
Gross margin86%-0.2pp
Operating margin44.8%+1.6pp
Net margin37.1%+0.2pp
FCF margin34.9%-15.2pp

Returns & leverage

See full
Return on equity24.5%-4.6pp
Debt / equity0×0.0×
Current ratio7.1×+1.0×

Where this comes from

Calculated from Catalyst Pharmaceutical’s reported figures.

$3.0Bmarket cap+$2.7Mtotal debt−$755.9Mcash and equivalents=$2.27B

The official record: Catalyst Pharmaceutical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Catalyst Pharmaceutical's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Catalyst Pharmaceutical's enterprise value?
Catalyst Pharmaceutical (CPRX) reported enterprise value of $2.27B in Q1 2026.
How has Catalyst Pharmaceutical's enterprise value changed year-over-year?
Catalyst Pharmaceutical's enterprise value decreased by 4.1% year-over-year, from $2.37B to $2.27B.
What is the long-term trend for Catalyst Pharmaceutical's enterprise value?
Over 5 years (2020 to 2025), Catalyst Pharmaceutical's enterprise value has grown at a 58.8% compound annual growth rate (CAGR), from $214.2M to $2.16B.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.